Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor

Keizer, H. J.; Messemer, Jonathan E.; Toner, Guy C.; Koops, Heimen Schraffordt; Fosså, Sophie D.; Gerl, Arthur; Sleijfer, Dirk; Donohue, John P.; Habbema, J. Dik F.

doi:10.1002/(sici)1097-0142(19970115)79:2<345::aid-cncr18>3.3.co;2-e

Cited by 27 publications

(39 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most common surgical approach, RPLND, is not without risk, however, and longterm morbidity is common even in experienced hands. The histology of resected residual tissue in the surgery group presented here (differentiated teratoma 50%, necrosis/fibrosis 31.75%, active cancer 18.75%) is similar in content to two recently published large combined series (Steyerberg et al, 1997;Stenning et al, 1998). Overall and progression-free survival curves were also similar.…”

Section: Discussionsupporting

confidence: 75%

Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours

et al. 2000

View full text Add to dashboard Cite

Summary This retrospective study was undertaken to determine the outcome of patients with non-seminomatous germ cell tumour who achieved a serological complete response but who had residual radiologic abnormalities upon completion of primary platinum-based chemotherapy. This was an analysis of 76 consecutive patients treated at Mount Vernon Hospital between 1983 and 1997. The patients were placed into two groups based upon whether they had surgical resection (surgery group, 48 patients) or observation (observation group, 28 patients) of residual radiologic masses on completion of initial chemotherapy (to enter the surgery group, complete surgical resection must have been achieved). The primary end-points were progression-free and overall survival. The percentage of patients alive with median followup 66 months was 90% for the surgery group and 80% for the observation group (P = 0.53, not significant). The percentage of patients continuously disease-free was 70% in the surgery group and 80% in the observation group (P = 0.31, not significant). In the small sub-group of patients with differentiated teratoma (TD) in the primary lesion who were observed, there was no excess risk of relapse or death. Patients who achieve a serological complete response after primary chemotherapy, but are left with ≤ 2 cm radiological masses that are not cystic and have responded, can be safely observed with diligent follow-up.

show abstract

Section: Discussionsupporting

confidence: 75%

Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours

et al. 2000

View full text Add to dashboard Cite

show abstract

“…In contrast, during several investigation, the application of the above mentioned criteria resulted in a false negative prediction of approximately 20%. And in some studies no factors has been identified for residual lung or mediastinal mass that could be used to select a group of patients who could safely avoid surgery 1,2,4,5 . If serum markers have normalized after chemotherapy, resection of all residual abnormalities on imaging studies of the mediastinum is recommended 2,3 .…”

Section: Discussionmentioning

confidence: 99%

Giant residual non-seminonatous mediastinal mass

Ocaña¹,

Ceballos

Marcos

et al. 2004

Oncología (Barc.)

View full text Add to dashboard Cite

Summary• Purpose: To point out the difficult therapeutic management of mediastinal germ-cell tumors and the residual masses.• Material and methods: We present a patient with a mediastinal non-seminomatous germcell tumor and the therapeutic management of the residual mass.• Results and conclusion: Surgical resection is the therapeutic attitude with regard to a resi- • Material y Métodos: se presenta el caso de un paciente con un tumor germinal no seminomatoso mediastínico y el manejo terapéutico de la masa residual.• Conclusiones: ante una masa residual no seminomatosa mediastínica con marcadores negativos la actitud terapéutica es la quirúrgica.Palabras clave: Masa mediastínica. Tumor germinal. Masa residual.

show abstract

“…The well-known refractory nature of fibrotic tissue to radiation and chemotherapy further supports this theory [15]. These features, often seen with retroperitoneal metastases treated with chemotherapy, may persist unchanged or slowly regress along the course of many years [10,15,19].…”

Section: Fibrosismentioning

confidence: 90%

Structural changes induced by antineoplastic therapies: keys to evaluate tumor response to treatment

2001

View full text Add to dashboard Cite

The criteria to define therapeutic response in oncology are those proposed by Miller, characterized by four response categories (complete response, partial response, no change, progression of disease), and based upon both measurable and non-measurable (and otherwise assessable) morphological parameters in comparison with baseline and subsequently modified following the Response Evaluation Criteria In Solid Tumors. In addition to these classical morphological criteria, we review the predictive value of structural changes in the evaluation of response to antineoplastic therapies. The goal of the present review is to evaluate in detail structural variations (calcification, fibrosis, differentiation, necrosis, cavitation, vascularization, edema, and pseudocapsule formation) induced by therapy, and to ascertain their significance in terms of biological evolution of the neoplastic process.

show abstract

Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor

Cited by 27 publications

References 1 publication

Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours

Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours

Giant residual non-seminonatous mediastinal mass

Structural changes induced by antineoplastic therapies: keys to evaluate tumor response to treatment

Contact Info

Product

Resources

About